Last reviewed · How we verify

Patch, Nicotine

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule

Nicotine binds to nicotinic acetylcholine receptors in the central and peripheral nervous system to reduce cravings and withdrawal symptoms during smoking cessation.

Nicotine binds to nicotinic acetylcholine receptors in the central and peripheral nervous system to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid.

At a glance

Generic namePatch, Nicotine
SponsorAssistance Publique - Hôpitaux de Paris
Drug classNicotinic acetylcholine receptor agonist
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaAddiction Medicine / Smoking Cessation
PhaseFDA-approved

Mechanism of action

Nicotine patches deliver nicotine transdermally at a controlled rate, maintaining steady plasma levels that satisfy nicotine dependence without the combustion products of cigarettes. By occupying nicotinic acetylcholine receptors, nicotine reduces the reward-seeking behavior and withdrawal symptoms associated with smoking cessation, facilitating abstinence.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: